PhotoFix
DevicePhotoFix Patch Implantation
NCT Number: NCT03669042
The objective of this post-market clinical follow-up study is to evaluate the clinical outcomes of patients receiving PhotoFix as a patch within a vascular repair or reconstruction procedure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
University of Arizona, Tucson, Arizona, United States
PhotoFix is prepared from bovine pericardium, which is stabilized using a dye-mediated photo-oxidation process and sterilized using aseptic processing techniques. The primary endpoint for patients with carotid artery stenosis (CAS) undergoing carotid endarterectomies (CEA) will be rate of ipsilateral central neurologic events; the primary endpoint for all other vascular procedures will be primary patency. The secondary endpoints include all-cause reoperation rate, device-related reoperation rate, explant rate, restenosis rate, secondary patency (hemodialysis access repair (HAR) only) and survival. A goal of 100 patients will be enrolled at approximately 10 sites. The enrollment period will span a minimum of 8 months from Institutional Review Board (IRB) approval and site activation. Candidates for this study are adults who require vascular repair or reconstruction surgery that necessitates the use of a patch. Patients will be consented pre-operatively and enrolled patients will be followed for approximately 6 months after PhotoFix surgery. Data will be collected at 5 time points: baseline (pre-operatively), intra-operatively, 1 month post-operatively, 3 months post-operatively, and 6 months post-operatively.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PhotoFix Patch Implantation
Time frame: Up to 6 months, post-op
For cases of carotid endarterectomy (CEA) only: Percent of patients who experienced at least one of the central neurologic events of interest (transient ischemic attack, amaurosis fugax, stroke, carotid occlusion).
Time frame: Up to 6 months, post-op
For all other procedures (non-CEAs): Loss of patency includes loss of previously palpable pulses, presentation of recurrent symptoms, a drop in ABI>0.15 in the case of lower limb artery repair, Doppler ultrasound findings of occlusion, angiography of the affected vessel or a combination of these. Loss of patency will also be considered if an intervention to restore or maintain patency is documented.
Time frame: Up to 6 months, post-op
Percent of patients surviving
Time frame: Up to 6 months, post-op
Percent of patients requiring re-operations
Time frame: Up to 6 months, post-op
Percent of patients requiring unplanned re-operations that are documented as possibly, probably or definitely, device-related.
Time frame: Up to 6 months, post-op
Percent of patients requiring device explants. Explants will include the removal of PhotoFix for any reason after implantation.
Time frame: Up to 6 months, post-op
Percent of patients who experienced at least one adverse event.
Time frame: Up to 6 months, post-op
Percent of patients who develop stenosis. Stenosis is considered as the recurrence of abnormal narrowing of an artery or vein after corrective surgery. Categorization of stenosis ≥ 50% will occur if data is available.
Time frame: Up to 6 months, post-op
For all hemodialysis access repairs only: Time from implantation to the point where the access is abandoned.
Artivion Inc.
Industry
Post-market, Prospective Evaluation of PHOTO-oxidized Decellularized Bovine Pericardium Used as a Patch in Vascular Repair and Reconstruction Surgery
Acronym: PHOTO-V
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03898570
Arterial Occlusive Diseases, Arteriosclerosis
Palo Alto, California, United States
View Trial DetailsNCT02719665
Arterial Occlusive Diseases, Arteriosclerosis
San Francisco, California, United States
View Trial DetailsNCT03496948
Arterial Occlusive Diseases, Arteriosclerosis
Hamburg, Germany
View Trial DetailsNCT02016755
Arterial Occlusive Diseases, Arteriosclerosis
Lebanon, New Hampshire, United States
View Trial Details